On September 4, 2021 Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as "Dr. Reddy’s"), reported that it has entered into a definitive agreement with Citius Pharmaceuticals, Inc. ("Citius") pursuant to which it sold all of its rights to E7777 (an engineered IL-2-diphtheria toxin fusion protein) and certain related assets (Press release, Dr Reddy’s, SEP 4, 2021, View Source [SID1234587243]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the terms of agreement, Dr. Reddy’s will receive $40 million upfront upon the closing of the transaction, followed by approval milestone payment of up to $40 million related to the CTCL (cutaneous T-cell lymphoma) indication approval and up to $70 million for additional indication approvals. Further, Dr. Reddy’s will receive certain sales-based milestones and tiered earn-out payments.

In March 2016, Dr. Reddy’s had acquired the exclusive global rights (excluding Japan and Asia) to the investigational anti-cancer agent E7777 from Eisai Co. Ltd.

Erez Israeli, Chief Executive Officer, Dr. Reddy’s, said: "Addressing unmet patient needs in oncology remains a prime focus area for us. E7777 has significant potential as an important component of systemic therapy for CTCL and other cancers. Post acquiring from Eisai, significant progress was made on the CTCL development front. We are confident of Citius’ ability to realize the full potential of E7777 in the treatment of CTCL as well as in their ability to develop this promising drug for additional oncology and immuno-oncology indications."

On September 3, 2021, Inhibrx, Inc. (the "Company") reported that it entered into an Open Market SaleSM Agreement (the "Sales Agreement") with Jefferies LLC, as sales agent (the "Agent"), pursuant to which the Company may offer and sell, from time to time, through the Agent (the "Offering") shares of its common stock (the "Shares") (Filing, 8-K, Inhibrx, SEP 3, 2021, View Source [SID1234587232]). Any Shares offered and sold in the Offering will be issued pursuant to the Company’s Registration Statement on Form S-3, as supplemented by the Company’s prospectus supplement dated as of September 3, 2021, filed with the Securities and Exchange Commission (the "Registration Statement"). Pursuant to the Registration Statement, the Company may offer and sell from time to time up to $200,000,000 Shares pursuant to the Sales Agreement.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Subject to the terms and conditions of the Sales Agreement, the Agent will use its commercially reasonable efforts to sell the Shares from time to time, based upon the Company’s instructions. Under the Sales Agreement, the Agent may sell the Shares by any method permitted by law deemed to be an "at the market offering" as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended (the "Securities Act"), including sales made directly on the Nasdaq Global Market or on any other existing trading market for the Shares.

The Company has no obligation to sell any of the Shares, and may at any time suspend offers under the Sales Agreement. The Offering will terminate as permitted in the Sales Agreement. The Sales Agreement contains representations and warranties for the benefit of the Company and the Agent and other terms customary for similar agreements.

Under the terms of the Sales Agreement, the Agent will be entitled to a commission at a rate equal to 3.0% of the gross proceeds from each sale of Shares under the Sales Agreement. The Company will also reimburse the Agent for certain expenses incurred in connection with the Sales Agreement, and has agreed to provide indemnification and contribution to the Agent with respect to certain liabilities, including liabilities under the Securities Act.

The Company currently intends to use any net proceeds from the Offering for working capital and general corporate purposes, including research and development expenses and capital expenditures.

The foregoing description of the Sales Agreement is not complete and is qualified in its entirety by reference to the full text of the form of the Sales Agreement filed as Exhibit 1.1 hereto, which is incorporated herein by reference.

This Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy the Shares, nor shall there be any offer, solicitation or sale of the Shares in any state or country in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or country.
The opinion of the Company’s counsel regarding the validity of the Shares is incorporated herein by reference as Exhibit 5.1 to the Company’s Registration Statement.

On September 3, 2021 Perrigo Company plc (NYSE; TASE: PRGO), reported that Perrigo President and CEO, Murray S. Kessler, and CFO, Ray Silcock, are scheduled to participate in investor meetings at the Barclays Global Consumer Staples Conference on Thursday, September 9 (Press release, Perrigo Company, SEP 3, 2021, View Source [SID1234587233]). The Company will not be making a formal presentation.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On September 3, 2021 BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) reported that the company will present at the 2021 Virtual Wells Fargo Healthcare Conference on Friday, September 10, 2021 at 1:20 p.m. ET and at the H.C. Wainwright 23rd Annual Global Investment Conference (virtual) (Press release, BioCryst Pharmaceuticals, SEP 3, 2021, View Source [SID1234587218]). The H.C. Wainwright presentation will be available on-demand in the Investors section of BioCryst’s website starting at 7:00 a.m. ET on Monday, September 13, 2021.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Links to the live audio webcast of the Wells Fargo presentation and replays of both presentations may be accessed in the Investors section of BioCryst’s website at http://www.biocryst.com.

On September 3, 2021 Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL) therapeutic platform, reported that it will participate in the H.C. Wainwright 23rd Annual Global Investment Conference, which is being held virtually from September 13 to 15, 2021 (Press release, Phio Pharmaceuticals, SEP 3, 2021, View Source [SID1234587234]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Phio Company Presentation Details:

Speaker: Dr. Gerrit Dispersyn, President & CEO of Phio Pharmaceuticals
Time/Date: Available starting at 7:00 AM ET on Monday, September 13th
Webcast: Registration (Click Here)
Replay: Interested parties may also access a replay of the Company presentation through the "Investors – Events and Presentations" section of the Company’s website (click here). The webcast will be archived and available on the Company’s website for 90 days.

For more information on the conference, or to schedule a one-on-one meeting, please contact a H.C. Wainwright representative.